During the course of the next decade, the oncology market will continue to evolve. To examine the changes that will likely take place over the next 10 years, the inVentiv Health Consulting (formerly Campbell Alliance) second-annual Oncology Index study is focused on the theme of maximizing value in oncology. Specifically, the study addresses the implications for the pharmaceutical industry from the standpoint of identifying value, developing value, and delivering value.
This report is built on the inVentiv Consulting team's experience from more than 300 oncology projects in the past three years, during which time we worked with nearly all of the top oncology manufacturers globally and the vast majority of new oncology product launches. The work covered a broad range of project types, from portfolio strategy to clinical development and commercialization.
A white paper summarizing the results of the 2013 Oncology Index study is available by clicking here.
You may also access a white paper highlighting the 2012 Oncology Index study here.